Blythe D Shepard, Jennifer Chau, Ryan Kurtz, Avi Z Rosenberg, Pinaki Sarder, Samuel P Border, Brandon Ginley, Olga Rodriguez, Chris Albanese, Grace Knoer, Aarenee Greene, Aline M A De Souza, Suman Ranjit, Moshe Levi, Carolyn M Ecelbarger
Sodium-glucose cotransporter, type 2 inhibitors (SGLT2i) are emerging as the gold standard for treatment of type 2 diabetes (T2D) with renal protective benefits independent of glucose lowering. We took a high-level approach to evaluate the effects of the SGLT2i, empagliflozin (EMPA) on renal metabolism and function in a prediabetic model of metabolic syndrome. Male and female 12-wk-old TallyHo (TH) mice, and their closest genetic lean strain (Swiss-Webster, SW) were treated with a high-milk-fat diet (HMFD) plus/minus EMPA (@0...
April 1, 2024: American Journal of Physiology. Cell Physiology